These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38822527)

  • 1. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
    Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
    Mol Ther; 2024 May; ():. PubMed ID: 38822527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice.
    Sengsayadeth S; Savani BN; Oluwole O; Dholaria B
    EJHaem; 2022 Jan; 3(Suppl 1):6-10. PubMed ID: 35844299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific CAR T-cells for B-cell Malignancies.
    Furqan F; Shah NN
    Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies.
    Borogovac A; Siddiqi T
    Semin Hematol; 2024 Apr; 61(2):119-130. PubMed ID: 38290860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
    Roex G; Feys T; Beguin Y; Kerre T; Poiré X; Lewalle P; Vandenberghe P; Bron D; Anguille S
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32102267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies in haematological malignancies.
    Viardot A; Bargou R
    Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
    Yang Z; Wang Y
    Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
    Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
    Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.
    van Bruggen JAC; Martens AWJ; Tonino SH; Kater AP
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33353234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
    Dabkowska A; Domka K; Firczuk M
    Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
    Salvaris R; Ong J; Gregory GP
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
    Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
    Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
    Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
    Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
    Shirouchi Y; Maruyama D
    Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirecting T cells to hematological malignancies with bispecific antibodies.
    Velasquez MP; Bonifant CL; Gottschalk S
    Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.